Market research
GRFS Grifols SA ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5B
- P/E ratio
- 10.39
- Analyst target
- 10.865
- Dividend yield
- 3.5%
- Beta
- 1.19
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- US3984384087
- Market cap
- 5B
- P/E ratio
- 10.39
- Analyst target
- 10.865
- Dividend yield
- 3.5%
- Beta
- 1.19
About
About Grifols SA ADR
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GRFS discussion.
5 years, 4 months ago
Grifols, S.A is currently in a long term downtrend where the price is trading 6.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
Grifols, S.A's total revenue sank by 3.8% to $1B since the same quarter in the previous year.
Its net income has increased by 10.7% to $223M since the same quarter in the previous year.
Finally, its free cash flow grew by 117.3% to $156M since the same quarter in the previous year.
Based on the above factors, Grifols, S.A gets an overall score of 3/5.